• Publications
  • Influence
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
BACKGROUND Heparin-induced thrombocytopenia, defined by the presence of heparin-dependent IgG antibodies, typically occurs five or more days after the start of heparin therapy and can be complicatedExpand
Use of antithrombotic agents during pregnancy.
Oral anticoagulant therapy should be avoided in the weeks before delivery because of the risk of serious perinatal bleeding caused by the trauma of delivery to the antICOagulated fetus, and the safety of aspirin during the first trimester of pregnancy is still a subject of debate. Expand
The Role of Venous Ultrasonography in the Diagnosis of Suspected Deep Venous Thrombosis and Pulmonary Embolism
The strengths and weaknesses of venous ultrasonography are considered in patients with the five clinical presentations of suspected venous thromboembolism and the criteria used to diagnose thrombosis often vary among examiners. Expand
Antiphospholipid antibodies and venous thromboembolism.
The presence of APLA in patients with VTE was not associated with resistance to a conventional intensity of warfarin or an increased risk of recurrent VTE after discontinuation of warFarin, and a larger study should address these issues in a subgroup of patients withVTE and LA. Expand
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Theheparin assay is a safe and effective method for monitoring heparin treatment in patients with acute venous thromboembolism whose APTT remains subtherapeutic despite large daily doses of heparIn such patients, dosage escalation can be avoided if the hepar in level is therapeutic. Expand
Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
A trial was conducted to evaluate the efficacy of only four weeks of warfarin in patients at low risk of recurrent venous thromboembolism and found that over the entire 11 months of follow-up, 12 placebo patients developed recurrence compared to sevenwarfarin patients, P = 0.009. Expand
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.
Low molecular weightHeparin is significantly less hemorrhagic than standard unfractionated heparin; the difference in the rate of deep vein thrombosis, although not statistically significant (P greater than 0.2), favors the use of LMWheparin. Expand
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
A double-blind randomized trial has been conducted in which patients with objectively established acute symptomatic pulmonary embolism who were receiving heparin were allocated to either a 2-minute infusion of rt-PA at a dose of 0.6 mg/kg or saline placebo, suggesting that a bolus regimen of rT-PA produces accelerated thrombolysis and provides an alternative and convenient approach to thROMbolytic therapy in patients with pulmonary emblism. Expand
Prevention and treatment of postphlebitic syndrome: results of a 3-part study.
Most patients do not have PPS 1 year after proximal deep venous thrombosis, and do not require stockings, but the small numbers preclude definitive conclusions. Expand
Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and d-dimer Testing
A prospective cohort study in which additional diagnostic testing and anticoagulant therapy were withheld in consecutive outpatients presenting with a suspected first episode of deep venous thrombosis who had a low pretest probability and a negative result on a whole-blood d-dimer test was performed. Expand